UNSPSC 51142561: Piribedil mesilate or mesylate

This classification denotes a dopamine agonist with the molecular formula C16H18N4O2.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1U37NGM6KK, chemically known as 2-(4-(1,3-benzodioxol-5-ylmethyl)piperazinyl)pyrimidinium methanesulphonate but more generally known as piribedil mesylate, which bears US NIH Compound Identifier 198284. European Medicines Agency schedules Piribedil mesylate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21569.

Most nations, for tariff and trade purposes, schedule piribedil mesylate under HS 29349990. As of Q4 2014, PIRIBEDIL MESYLATE remains US FDA's Preferred Term for this commodity. SMILES: CS(=O)(=O)O.C1CNC(NC1)N2CCN(CC2)CC3CCC4C(C3)OCO4.

UNSPSC 51142561 Piribedil mesilate or mesylate is a Commodity code that nominally identifies a specific pharmaceutical compound, but recent state and local solicitations tagged with this code show virtually no activity related to piribedil itself. Instead, the recorded opportunities span pharmaceutical procurement more broadly — naloxone supply, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and OTC products. The mismatch suggests either miscoding in the state and local procurement systems or that the code is being used as a catch-all for general pharmaceutical sourcing rather than piribedil-specific purchasing. State and local issuing bodies soliciting under this code include county health departments, state health and human services commissions, and cooperative purchasing alliances that span multiple state jurisdictions.

Geographic activity centers on Florida and Texas, with multistate reach through the Minnesota Multistate Cooperative Purchasing Alliance. Recent opportunities include Seminole County, Florida's IFB for naloxone and drug deactivation systems (due July 26, 2023), the Texas Health and Human Services Commission's RFI on direct-to-manufacturer prescription programs (due April 3, 2026), and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products open to participating states including Oregon (due March 26, 2026). Given the absence of piribedil-specific demand and the low volume of recent solicitations under the code, current market activity is minimal and unlikely to support a focused pursuit strategy.